Andrew L. Concoff

2 months ago | the-rheumatologist.org | Daniel Solomon |Andrew L. Concoff

Over our 25 years as rheumatologists, care has advanced greatly. We each completed our rheumatology training in the late 1990s when both infliximab and etanercept first arrived on the U.S. market, ushering in the era of biologics in rheumatology. Since this time, our greater understanding of the immunologic basis of many rheumatic diseases has translated into a growing list of targeted therapies.